Your browser doesn't support javascript.
Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C. / [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
An Pediatr (Barc) ; 90(3): 141-147, 2019 Mar.
Artigo em Espanhol | MEDLINE | ID: mdl-30126773


Hepatitis C virus infection is world health problem. The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients.


Eligible patients to be treated with ledipasvir/sofosbuvir were patients from 6 to 18 years old with a chronic HCV genotype 1 or 4 infection. The duration and doses of antiviral drugs were changed depending on patient age, fibrosis stage, and PEGylated interferon+ribavirin experience status. The primary efficacy endpoint was the percentage of patients with a sustained virological response 12 weeks post-treatment.


A total of nine patients (7 males) with a median age of 14.8 years (8.48-17.91) were treated with ledipasvir/sofosbuvir combination. Five patients received previous treatment with PEGylated interferon+ribavirin during a median of 8.5 months (3-12 months). Eight patients had some degree of fibrosis (1 patient presented with F1, three patients F2, 2 patients F3, and 2 patients F4). The median pre-treatment viral load was 6.2 Log [5.9-6.8] with the HCV RNA becoming negative six weeks after starting the treatment in 100% of the patients. All patients maintained a sustained viral response at 12 weeks. Three patients (33.3%) had some type of adverse effect (2 headache and one oral thrush). The median post-treatment follow-up was 24 weeks (12-104).


Treatment with ledipasvir/sofosbuvir in paediatric patients with chronic HCV infection genotype 1 and 4 is safe and effective with SVR12 and similar to those reported in adults.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Antivirais / Uridina Monofosfato / Benzimidazóis / Hepacivirus / Hepatite C Crônica / Fluorenos Aspecto clínico: Prognóstico Limite: Adolescente / Criança / Feminino / Humanos / Masculino Idioma: Espanhol Revista: An Pediatr (Barc) Assunto da revista: Pediatria Ano de publicação: 2019 Tipo de documento: Artigo